Wall Street brokerages predict that West Pharmaceutical Services Inc. (NYSE:WST) will announce $435.00 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for West Pharmaceutical Services’ earnings, with the lowest sales estimate coming in at $430.00 million and the highest estimate coming in at $440.00 million. West Pharmaceutical Services posted sales of $415.60 million during the same quarter last year, which suggests a positive year over year growth rate of 4.7%. The business is expected to announce its next earnings results on Thursday, February 21st.

According to Zacks, analysts expect that West Pharmaceutical Services will report full-year sales of $1.73 billion for the current fiscal year, with estimates ranging from $1.72 billion to $1.73 billion. For the next fiscal year, analysts anticipate that the business will report sales of $1.85 billion, with estimates ranging from $1.84 billion to $1.86 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, October 25th. The medical instruments supplier reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.06. West Pharmaceutical Services had a return on equity of 15.78% and a net margin of 9.06%. The company had revenue of $431.70 million during the quarter, compared to analysts’ expectations of $427.55 million.

Several research analysts have recently issued reports on WST shares. ValuEngine raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $135.00 target price for the company in a research note on Saturday, October 13th.

A number of hedge funds have recently made changes to their positions in WST. Alps Advisors Inc. bought a new position in West Pharmaceutical Services during the second quarter valued at about $206,000. Strs Ohio bought a new position in West Pharmaceutical Services during the second quarter valued at about $302,000. US Bancorp DE boosted its stake in West Pharmaceutical Services by 11.4% during the second quarter. US Bancorp DE now owns 17,841 shares of the medical instruments supplier’s stock valued at $1,772,000 after buying an additional 1,826 shares in the last quarter. Private Advisor Group LLC bought a new position in West Pharmaceutical Services during the second quarter valued at about $304,000. Finally, Federated Investors Inc. PA boosted its stake in West Pharmaceutical Services by 2.4% during the second quarter. Federated Investors Inc. PA now owns 29,835 shares of the medical instruments supplier’s stock valued at $2,962,000 after buying an additional 691 shares in the last quarter. 92.50% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:WST traded down $0.03 on Friday, hitting $103.83. The company’s stock had a trading volume of 156,805 shares, compared to its average volume of 376,313. West Pharmaceutical Services has a 12 month low of $82.74 and a 12 month high of $125.09. The stock has a market cap of $7.69 billion, a price-to-earnings ratio of 37.35, a PEG ratio of 3.68 and a beta of 1.21. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.23 and a current ratio of 2.94.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 6th. Investors of record on Wednesday, January 23rd will be paid a dividend of $0.15 per share. The ex-dividend date of this dividend is Tuesday, January 22nd. This represents a $0.60 annualized dividend and a yield of 0.58%. West Pharmaceutical Services’s dividend payout ratio is currently 21.58%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: The risks of owning bonds

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.